No significant pharmacokinetic interaction observed between cagrilintide and semaglutide 1-3
Net cash used in operating activities for the year ended December 31, 2023 was approximately $36,100,000 which includes a net loss of approximately $44,603,000, adjusted for non-cash expenses of approximately $4,409,000, principally related to stock-based compensation expense of $3,470,000, amortization of debt discount of $824,000, depreciation and amortization expense of $641,000, and net amortization on discount of investments of $506,000, and approximately $4,094,000 of cash used by net working capital items, principally related to the increases in accrued expenses of $5,031,000 and accounts payable of $1,028,000 and a decrease in operating lease right-of-use asset amortization of $821,000 offset by an increase in prepaid expenses of $1,470,000 and a decrease in operating lease liabilities of $1,281,000
No coffee, no other tablets, no breakfast
The medications are HSA/FSA eligible, further reducing out-of-pocket costs for qualifying patients
Medivera Compounding Pharmacy Missouri, 503B
V., Ostrovtsova, S
